BIONAUT PHARMACEUTICALS INC has a total of 17 patent applications. Its first patent ever was published in 2001. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are MATINAS BIOPHARMA NANOTECHNOLOGIES INC, BOULIKAS TENI and ASTEX PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Steroids | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Khodadoust Mehran | 15 |
#2 | Sharma Ajay | 15 |
#3 | Bruening Reimar | 3 |
#4 | Schwarz Oliver | 1 |
#5 | Hess Hans-Jurgen | 1 |
#6 | Hussoin Sajjat | 1 |
#7 | Khodadoust Mehran M | 1 |
Publication | Filing date | Title |
---|---|---|
US2008027010A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | |
EP1928470A2 | Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders | |
US2007105790A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | |
WO2006029018A2 | Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors | |
US2006135442A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | |
US2006135468A1 | Treatment of refractory cancers using NA+/K+ ATPase inhibitors |